Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to determine the maximum tolerated dose (MTD) for various treatment durations of BIBW
2992 when administered in combination with docetaxel as determined by drug-related adverse
events (AEs) as well as Pharmacokinetics, overall safety and antitumor efficacy.